Publication

Gain-of-function mutations in the gene encoding the tyrosine phosphatase SHP2 induce hydrocephalus in a catalytically dependent manner

Downloadable Content

Persistent URL
Last modified
  • 05/15/2025
Type of Material
Authors
    Hong Zheng, Emory UniversityWen-Mei Yu, Emory UniversityRonald R. Waclaw, Cincinnati Children’s Hospital Medical CenterMaria I. Kontaridis, Harvard Medical SchoolBenjamin G. Neel, New York UniversityCheng-Kui Qu, Emory University
Language
  • English
Date
  • 2018-03-20
Publisher
  • American Association for the Advancement of Science
Publication Version
Copyright Statement
  • © 2018 The Authors, All rights reserved.
Final Published Version (URL)
Title of Journal or Parent Work
ISSN
  • 1945-0877
Volume
  • 11
Issue
  • 522
Start Page
  • eaao1591
End Page
  • eaao1591
Grant/Funding Information
  • This work was supported by National Institutes of Health grants HL130995, DK092722 and HD087760 (to C.K.Q.), NS088529 (to R.R.W.), and HL114775 (to M.I.K.).
Supplemental Material (URL)
Abstract
  • Catalytically activating mutations in Ptpn11, which encodes the protein tyrosine phosphatase SHP2, cause 50% of Noonan syndrome (NS) cases, whereas inactivating mutations in Ptpn11 are responsible for nearly all cases of the similar, but distinct, developmental disorder Noonan syndrome with multiple lentigines (NSML; formerly called LEOPARD syndrome). However, both types of disease mutations are gain-of-function mutations because they cause SHP2 to constitutively adopt an open conformation. We found that the catalytic activity of SHP2 was required for the pathogenic effects of gain-of-function, disease-Associated mutations on the development of hydrocephalus in the mouse. Targeted pan-neuronal knockin of a Ptpn11 allele encoding the active SHP2 E76K mutant resulted in hydrocephalus due to aberrant development of ependymal cells and their cilia. These pathogenic effects of the E76K mutation were suppressed by the additional mutation C459S, which abolished the catalytic activity of SHP2. Moreover, ependymal cells in NSML mice bearing the inactive SHP2 mutant Y279C were also unaffected. Mechanistically, the SHP2 E76K mutant induced developmental defects in ependymal cells by enhancing dephosphorylation and inhibition of the transcription activator STAT3. Whereas STAT3 activity was reduced in Ptpn11E76K/+cells, the activities of the kinases ERK and AKT were enhanced, and neural cell-specific Stat3 knockout mice also manifested developmental defects in ependymal cells and cilia. These genetic and biochemical data demonstrate a catalytic-dependent role of SHP2 gain-of-function disease mutants in the pathogenesis of hydrocephalus.
Author Notes
  • Corresponding author: Cheng-Kui Qu, Department of Pediatrics, Aflac Cancer and Blood Disorders Center, Children’s Healthcare of Atlanta, Emory University School of Medicine, Atlanta, GA 30322. cheng-kui.qu@emory.edu.
Keywords
Research Categories
  • Health Sciences, Oncology
  • Biology, Molecular

Tools

Relations

In Collection:

Items